RNA Modifications in Cancer: Functions, Mechanisms, and Therapeutic Implications

Literature Cited

1. Aguilo F, Zhang F, Sancho A, Fidalgo M, Di Cecilia S et al. 2015. Coordination of m⁶A mRNA methylation and gene transcription by ZFP217 regulates pluripotency and reprogramming. Cell Stem Cell 17:689–704
   [Google Scholar]
2. Alarcon CR, Goodarzi H, Lee H, Liu X, Tavazoie S, Tavazoie SF 2015. HNRNPA2B1 is a mediator of m⁶A-dependent nuclear RNA processing events. Cell 162:1299–308
   [Google Scholar]
3. Alawi F, Lee MN. 2007. DKC1 is a direct and conserved transcriptional target of c-MYC. Biochem. Biophys. Res. Commun. 362:893–98
   [Google Scholar]
4. Amort T, Rieder D, Wille A, Khokhlova-Cubberley D, Riml C et al. 2017. Distinct 5-methylcytosine profiles in poly(A) RNA from mouse embryonic stem cells and brain. Genome Biol 18:1
   [Google Scholar]
5. Arango D, Sturgill D, Alhusaini N, Dillman AA, Sweet TJ et al. 2018. Acetylation of cytidine in mRNA promotes translation efficiency. Cell 175:1872–86.e24
   [Google Scholar]
6. Bansal H, Yihua Q, Iyer SP, Ganapathy S, Proia DA et al. 2014. WTAP is a novel oncogenic protein in acute myeloid leukemia. Leukemia 28:1171–74
   [Google Scholar]
7. Barbieri I, Tzelepis K, Pandolfini L, Shi J, Millan-Zambrano G et al. 2017. Promoter-bound METTL3 maintains myeloid leukaemia by m⁶A-dependent translation control. Nature 552:126–31
   [Google Scholar]
8. Bell JL, Wachter K, Muhleck B, Pazaitis N, Kohn M et al. 2013. Insulin-like growth factor 2 mRNA-binding proteins (IGF2BPs): post-transcriptional drivers of cancer progression. ? Cell. Mol. Life Sci. 70:2657–75
   [Google Scholar]
9. Bellodi C, Kopmar N, Ruggero D 2010. Deregulation of oncogene-induced senescence and p53 translational control in X-linked dyskeratosis congenita. EMBO J 29:1865–76
   [Google Scholar]
10. Boccaletto P, Machnicka MA, Purta E, Piatkowski P, Baginski B et al. 2018. MODOMICS: a database of RNA modification pathways. 2017 update. Nucleic Acids Res 46:D303–7
    [Google Scholar]
11. Carlile TM, Rojas-Duran MF, Zinshteyn B, Shin H, Bartoli KM, Gilbert WV 2014. Pseudouridine profiling reveals regulated mRNA pseudouridylation in yeast and human cells. Nature 515:143–46
    [Google Scholar]
12. Chen B, Ye F, Yu L, Jia G, Huang X et al. 2012. Development of cell-active N⁶-methyladenosine RNA demethylase FTO inhibitor. J. Am. Chem. Soc. 134:17963–71
    [Google Scholar]
13. Chen L, Li Y, Lin CH, Chan TH, Chow RK et al. 2013. Recoding RNA editing of AZIN1 predisposes to hepatocellular carcinoma. Nat. Med. 19:209–16
    [Google Scholar]
14. Chen M, Wei L, Law CT, Tsang FH, Shen J et al. 2018. RNA N⁶-methyladenosine methyltransferase-like 3 promotes liver cancer progression through YTHDF2-dependent posttranscriptional silencing of SOCS2. Hepatology 67:2254–70
    [Google Scholar]
15. Chen Z, Qi M, Shen B, Luo G, Wu Y et al. 2019. Transfer RNA demethylase ALKBH3 promotes cancer progression via induction of tRNA-derived small RNAs. Nucleic Acids Res 47:2533–45
    [Google Scholar]
16. Cheng JX, Chen L, Li Y, Cloe A, Yue M et al. 2018. RNA cytosine methylation and methyltransferases mediate chromatin organization and 5-azacytidine response and resistance in leukaemia. Nat. Commun. 9:1163
    [Google Scholar]
17. Cheng M, Sheng L, Gao Q, Xiong Q, Zhang H et al. 2019. The m⁶A methyltransferase METTL3 promotes bladder cancer progression via AFF4/NF-κB/MYC signaling network. Oncogene 38:3667–80
    [Google Scholar]
18. Choe J, Lin S, Zhang W, Liu Q, Wang L et al. 2018. mRNA circularization by METTL3-eIF3h enhances translation and promotes oncogenesis. Nature 561:556–60
    [Google Scholar]
19. Choudhury Y, Tay FC, Lam DH, Sandanaraj E, Tang C et al. 2012. Attenuated adenosine-to-inosine editing of microRNA-376a^* promotes invasiveness of glioblastoma cells. J. Clin. Investig. 122:4059–76
    [Google Scholar]
20. Cui Q, Shi H, Ye P, Li L, Qu Q et al. 2017. m⁶A RNA methylation regulates the self-renewal and tumorigenesis of glioblastoma stem cells. Cell Rep 18:2622–34
    [Google Scholar]
21. Davis FF, Allen FW. 1957. Ribonucleic acids from yeast which contain a fifth nucleotide. J. Biol. Chem. 227:907–15
    [Google Scholar]
22. Delatte B, Wang F, Ngoc LV, Collignon E, Bonvin E et al. 2016. Transcriptome-wide distribution and function of RNA hydroxymethylcytosine. Science 351:282–85
    [Google Scholar]
23. Deng X, Su R, Feng X, Wei M, Chen J 2018a. Role of N⁶-methyladenosine modification in cancer. Curr. Opin. Genet. Dev. 48:1–7
    [Google Scholar]
24. Deng X, Su R, Weng H, Huang H, Li Z, Chen J 2018b. RNA N⁶-methyladenosine modification in cancers: current status and perspectives. Cell Res 28:507–17
    [Google Scholar]
25. Desrosiers R, Friderici K, Rottman F 1974. Identification of methylated nucleosides in messenger RNA from Novikoff hepatoma cells. PNAS 71:3971–75
    [Google Scholar]
26. Dominissini D, Moshitch-Moshkovitz S, Schwartz S, Salmon-Divon M, Ungar L et al. 2012. Topology of the human and mouse m6A RNA methylomes revealed by m6A-seq. Nature 485:201–6
    [Google Scholar]
27. Dominissini D, Nachtergaele S, Moshitch-Moshkovitz S, Peer E, Kol N et al. 2016. The dynamic N¹-methyladenosine methylome in eukaryotic messenger RNA. Nature 530:441–46
    [Google Scholar]
28. Duhoux FP, Ameye G, Lambert C, Herman M, Iossifidis S et al. 2012. Novel head-to-head gene fusion of MLL with ZC3H13 in a JAK2 V617F-positive patient with essential thrombocythemia without blast cells. Leuk. Res. 36:e27–30
    [Google Scholar]
29. Frye M, Harada BT, Behm M, He C 2018. RNA modifications modulate gene expression during development. Science 361:1346–49
    [Google Scholar]
30. Frye M, Watt FM. 2006. The RNA methyltransferase Misu (NSun2) mediates Myc-induced proliferation and is upregulated in tumors. Curr. Biol. 16:971–81
    [Google Scholar]
31. Fu L, Qin YR, Ming XY, Zuo XB, Diao YW et al. 2017. RNA editing of SLC22A3 drives early tumor invasion and metastasis in familial esophageal cancer. PNAS 114:E4631–40
    [Google Scholar]
32. Gehrke CW, Kuo KC, Waalkes TP, Borek E 1979. Patterns of urinary excretion of modified nucleosides. Cancer Res 39:1150–53
    [Google Scholar]
33. Gong J, Li Y, Liu CJ, Xiang Y, Li C et al. 2017. A pan-cancer analysis of the expression and clinical relevance of small nucleolar RNAs in human cancer. Cell Rep 21:1968–81
    [Google Scholar]
34. Gumireddy K, Li A, Kossenkov AV, Sakurai M, Yan J et al. 2016. The mRNA-edited form of GABRA3 suppresses GABRA3-mediated Akt activation and breast cancer metastasis. Nat. Commun. 7:10715
    [Google Scholar]
35. Gutschner T, Hammerle M, Pazaitis N, Bley N, Fiskin E et al. 2014. Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) is an important protumorigenic factor in hepatocellular carcinoma. Hepatology 59:1900–11
    [Google Scholar]
36. Han D, Liu J, Chen C, Dong L, Liu Y et al. 2019. Anti-tumour immunity controlled through mRNA m⁶A methylation and YTHDF1 in dendritic cells. Nature 566:270–74
    [Google Scholar]
37. Han L, Diao L, Yu S, Xu X, Li J et al. 2015. The genomic landscape and clinical relevance of A-to-I RNA editing in human cancers. Cancer Cell 28:515–28
    [Google Scholar]
38. Han SW, Kim HP, Shin JY, Jeong EG, Lee WC et al. 2014. RNA editing in RHOQ promotes invasion potential in colorectal cancer. J. Exp. Med. 211:613–21
    [Google Scholar]
39. He Y, Hu H, Wang Y, Yuan H, Lu Z et al. 2018. ALKBH5 inhibits pancreatic cancer motility by decreasing long non-coding RNA KCNK15-AS1 methylation. Cell Physiol. Biochem. 48:838–46
    [Google Scholar]
40. Hotta K, Sho M, Fujimoto K, Shimada K, Yamato I et al. 2015. Clinical significance and therapeutic potential of prostate cancer antigen-1/ALKBH3 in human renal cell carcinoma. Oncol. Rep. 34:648–54
    [Google Scholar]
41. Hsu PJ, Zhu Y, Ma H, Guo Y, Shi X et al. 2017. Ythdc2 is an N⁶-methyladenosine binding protein that regulates mammalian spermatogenesis. Cell Res 27:1115–27
    [Google Scholar]
42. Huang H, Weng H, Sun W, Qin X, Shi H et al. 2018. Recognition of RNA N⁶-methyladenosine by IGF2BP proteins enhances mRNA stability and translation. Nat. Cell Biol. 20:285–95
    [Google Scholar]
43. Huang H, Weng H, Zhou K, Wu T, Zhao BS et al. 2019. Histone H3 trimethylation at lysine 36 guides m⁶A RNA modification co-transcriptionally. Nature 567:414–19
    [Google Scholar]
44. Huang W, Qi CB, Lv SW, Xie M, Feng YQ et al. 2016. Determination of DNA and RNA methylation in circulating tumor cells by mass spectrometry. Anal. Chem. 88:1378–84
    [Google Scholar]
45. Huang Y, Su R, Sheng Y, Dong L, Dong Z et al. 2019. Small-molecule targeting of oncogenic FTO demethylase in acute myeloid leukemia. Cancer Cell 35:677–91.e10
    [Google Scholar]
46. Huang Y, Yan J, Li Q, Li J, Gong S et al. 2015. Meclofenamic acid selectively inhibits FTO demethylation of m⁶A over ALKBH5. Nucleic Acids Res 43:373–84
    [Google Scholar]
47. Hussain S, Sajini AA, Blanco S, Dietmann S, Lombard P et al. 2013. NSun2-mediated cytosine-5 methylation of vault noncoding RNA determines its processing into regulatory small RNAs. Cell Rep 4:255–61
    [Google Scholar]
48. Jia G, Fu Y, Zhao X, Dai Q, Zheng G et al. 2011. N6-methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO. Nat. Chem. Biol. 7:885–87
    [Google Scholar]
49. Jiang Q, Crews LA, Barrett CL, Chun HJ, Court AC et al. 2013. ADAR1 promotes malignant progenitor reprogramming in chronic myeloid leukemia. PNAS 110:1041–46
    [Google Scholar]
50. Jin DI, Lee SW, Han ME, Kim HJ, Seo SA et al. 2012. Expression and roles of Wilms' tumor 1-associating protein in glioblastoma. Cancer Sci 103:2102–9
    [Google Scholar]
51. Kaklamani V, Yi N, Sadim M, Siziopikou K, Zhang K et al. 2011. The role of the fat mass and obesity associated gene (FTO) in breast cancer risk. BMC Med. Genet. 12:52
    [Google Scholar]
52. Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y et al. 2013. Integrated genomic characterization of endometrial carcinoma. Nature 497:67–73
    [Google Scholar]
53. Karijolich J, Yi C, Yu YT 2015. Transcriptome-wide dynamics of RNA pseudouridylation. Nat. Rev. Mol. Cell Biol. 16:581–85
    [Google Scholar]
54. Khoddami V, Cairns BR. 2013. Identification of direct targets and modified bases of RNA cytosine methyltransferases. Nat. Biotechnol. 31:458–64
    [Google Scholar]
55. Knuckles P, Lence T, Haussmann IU, Jacob D, Kreim N et al. 2018. Zc3h13/Flacc is required for adenosine methylation by bridging the mRNA-binding factor Rbm15/Spenito to the m⁶A machinery component Wtap/Fl(2)d. Genes Dev 32:415–29
    [Google Scholar]
56. Konishi N, Nakamura M, Ishida E, Shimada K, Mitsui E et al. 2005. High expression of a new marker PCA-1 in human prostate carcinoma. Clin. Cancer Res. 11:5090–97
    [Google Scholar]
57. Li A, Chen YS, Ping XL, Yang X, Xiao W et al. 2017. Cytoplasmic m⁶A reader YTHDF3 promotes mRNA translation. Cell Res 27:444–47
    [Google Scholar]
58. Li W, Zhang X, Lu X, You L, Song Y et al. 2017. 5-hydroxymethylcytosine signatures in circulating cell-free DNA as diagnostic biomarkers for human cancers. Cell Res 27:1243–57
    [Google Scholar]
59. Li X, Xiong X, Wang K, Wang L, Shu X et al. 2016. Transcriptome-wide mapping reveals reversible and dynamic N¹-methyladenosine methylome. Nat. Chem. Biol. 12:311–16
    [Google Scholar]
60. Li X, Zhu P, Ma S, Song J, Bai J et al. 2015. Chemical pulldown reveals dynamic pseudouridylation of the mammalian transcriptome. Nat. Chem. Biol. 11:592–97
    [Google Scholar]
61. Li Z, Weng H, Su R, Weng X, Zuo Z et al. 2017. FTO plays an oncogenic role in acute myeloid leukemia as a N⁶-methyladenosine RNA demethylase. Cancer Cell 31:127–41
    [Google Scholar]
62. Licht K, Hartl M, Amman F, Anrather D, Janisiw MP, Jantsch MF 2019. Inosine induces context-dependent recoding and translational stalling. Nucleic Acids Res 47:3–14
    [Google Scholar]
63. Lin S, Choe J, Du P, Triboulet R, Gregory RI 2016. The m⁶A methyltransferase METTL3 promotes translation in human cancer cells. Mol. Cell 62:335–45
    [Google Scholar]
64. Linder B, Grozhik AV, Olarerin-George AO, Meydan C, Mason CE, Jaffrey SR 2015. Single-nucleotide-resolution mapping of m6A and m6Am throughout the transcriptome. Nat. Methods 12:767–72
    [Google Scholar]
65. Liu J, Eckert MA, Harada BT, Liu SM, Lu Z et al. 2018a. m⁶A mRNA methylation regulates AKT activity to promote the proliferation and tumorigenicity of endometrial cancer. Nat. Cell Biol. 20:1074–83
    [Google Scholar]
66. Liu J, Ren D, Du Z, Wang H, Zhang H, Jin Y 2018b. m⁶A demethylase FTO facilitates tumor progression in lung squamous cell carcinoma by regulating MZF1 expression. Biochem. Biophys. Res. Commun. 502:456–64
    [Google Scholar]
67. Liu J, Yue Y, Han D, Wang X, Fu Y et al. 2014. A METTL3-METTL14 complex mediates mammalian nuclear RNA N⁶-adenosine methylation. Nat. Chem. Biol. 10:93–95
    [Google Scholar]
68. Liu N, Dai Q, Zheng G, He C, Parisien M, Pan T 2015. N⁶-methyladenosine-dependent RNA structural switches regulate RNA-protein interactions. Nature 518:560–64
    [Google Scholar]
69. Liu Y, Wang R, Zhang L, Li J, Lou K, Shi B 2017. The lipid metabolism gene FTO influences breast cancer cell energy metabolism via the PI3K/AKT signaling pathway. Oncol. Lett. 13:4685–90
    [Google Scholar]
70. Lovejoy AF, Riordan DP, Brown PO 2014. Transcriptome-wide mapping of pseudouridines: pseudouridine synthases modify specific mRNAs in S. cerevisiae. . PLOS ONE 9:e110799
    [Google Scholar]
71. Ma JZ, Yang F, Zhou CC, Liu F, Yuan JH et al. 2017. METTL14 suppresses the metastatic potential of hepatocellular carcinoma by modulating N⁶-methyladenosine-dependent primary microRNA processing. Hepatology 65:529–43
    [Google Scholar]
72. Ma Z, Morris SW, Valentine V, Li M, Herbrick JA et al. 2001. Fusion of two novel genes, RBM15 and MKL1, in the t(1;22)(p13;q13) of acute megakaryoblastic leukemia. Nat. Genet. 28:220–21
    [Google Scholar]
73. Maas S, Patt S, Schrey M, Rich A 2001. Underediting of glutamate receptor GluR-B mRNA in malignant gliomas. PNAS 98:14687–92
    [Google Scholar]
74. Mei YP, Liao JP, Shen J, Yu L, Liu BL et al. 2012. Small nucleolar RNA 42 acts as an oncogene in lung tumorigenesis. Oncogene 31:2794–804
    [Google Scholar]
75. Meyer KD, Patil DP, Zhou J, Zinoviev A, Skabkin MA et al. 2015. 5′ UTR m⁶A promotes cap-independent translation. Cell 163:999–1010
    [Google Scholar]
76. Meyer KD, Saletore Y, Zumbo P, Elemento O, Mason CE, Jaffrey SR 2012. Comprehensive analysis of mRNA methylation reveals enrichment in 3′ UTRs and near stop codons. Cell 149:1635–46
    [Google Scholar]
77. Montanaro L, Brigotti M, Clohessy J, Barbieri S, Ceccarelli C et al. 2006. Dyskerin expression influences the level of ribosomal RNA pseudo-uridylation and telomerase RNA component in human breast cancer. J. Pathol. 210:10–18
    [Google Scholar]
78. Motyl T, Traczyk Z, Ciesluk S, Daniewska-Michalska D, Kukulska W et al. 1993. Blood plasma pseudouridine in patients with malignant proliferative diseases. Eur. J. Clin. Chem. Clin. Biochem. 31:765–71
    [Google Scholar]
79. Muller S, Glass M, Singh AK, Haase J, Bley N et al. 2019. IGF2BP1 promotes SRF-dependent transcription in cancer in a m⁶A- and miRNA-dependent manner. Nucleic Acids Res 47:375–90
    [Google Scholar]
80. Nielsen HR, Nyholm K, Sjolin KE 1974. Relationship between urinary β-aminoisobutyric acid and transfer RNA turnover in cancer patients. Cancer Res 34:3428–32
    [Google Scholar]
81. Okugawa Y, Toiyama Y, Toden S, Mitoma H, Nagasaka T et al. 2017. Clinical significance of SNORA42 as an oncogene and a prognostic biomarker in colorectal cancer. Gut 66:107–17
    [Google Scholar]
82. Panneerdoss S, Eedunuri VK, Yadav P, Timilsina S, Rajamanickam S et al. 2018. Cross-talk among writers, readers, and erasers of m⁶A regulates cancer growth and progression. Sci. Adv. 4:eaar8263
    [Google Scholar]
83. Patil DP, Chen CK, Pickering BF, Chow A, Jackson C et al. 2016. m⁶A RNA methylation promotes XIST-mediated transcriptional repression. Nature 537:369–73
    [Google Scholar]
84. Paz N, Levanon EY, Amariglio N, Heimberger AB, Ram Z et al. 2007. Altered adenosine-to-inosine RNA editing in human cancer. Genome Res 17:1586–95
    [Google Scholar]
85. Pendleton KE, Chen B, Liu K, Hunter OV, Xie Y et al. 2017. The U6 snRNA m⁶A methyltransferase METTL16 regulates SAM synthetase intron retention. Cell 169:824–35.e14
    [Google Scholar]
86. Peng X, Xu X, Wang Y, Hawke DH, Yu S et al. 2018. A-to-I RNA editing contributes to proteomic diversity in cancer. Cancer Cell 33:817–28.e7
    [Google Scholar]
87. Penzo M, Guerrieri AN, Zacchini F, Trere D, Montanaro L 2017. RNA pseudouridylation in physiology and medicine: for better and for worse. Genes 8:11301
    [Google Scholar]
88. Perry RP, Kelley DE. 1974. Existence of methylated messenger RNA in mouse L cells. Cell 1:37–42
    [Google Scholar]
89. Ping XL, Sun BF, Wang L, Xiao W, Yang X et al. 2014. Mammalian WTAP is a regulatory subunit of the RNA N6-methyladenosine methyltransferase. Cell Res 24:177–89
    [Google Scholar]
90. Reddy R, Ro-Choi TS, Henning D, Shibata H, Choi YC, Busch H 1972. Modified nucleosides of nuclear and nucleolar low molecular weight ribonucleic acid. J. Biol. Chem. 247:7245–50
    [Google Scholar]
91. Ronchetti D, Mosca L, Cutrona G, Tuana G, Gentile M et al. 2013. Small nucleolar RNAs as new biomarkers in chronic lymphocytic leukemia. BMC Med. Genom. 6:27
    [Google Scholar]
92. Ronchetti D, Todoerti K, Tuana G, Agnelli L, Mosca L et al. 2012. The expression pattern of small nucleolar and small Cajal body-specific RNAs characterizes distinct molecular subtypes of multiple myeloma. Blood Cancer J 2:e96
    [Google Scholar]
93. Roundtree IA, Evans ME, Pan T, He C 2017. Dynamic RNA modifications in gene expression regulation. Cell 169:1187–200
    [Google Scholar]
94. Russo T, Colonna A, Salvatore F, Cimino F, Bridges S, Gurgo C 1984. Serum pseudouridine as a biochemical marker in the development of AKR mouse lymphoma. Cancer Res 44:2567–70
    [Google Scholar]
95. Schaefer M, Hagemann S, Hanna K, Lyko F 2009. Azacytidine inhibits RNA methylation at DNMT2 target sites in human cancer cell lines. Cancer Res 69:8127–32
    [Google Scholar]
96. Schwartz S, Bernstein DA, Mumbach MR, Jovanovic M, Herbst RH et al. 2014a. Transcriptome-wide mapping reveals widespread dynamic-regulated pseudouridylation of ncRNA and mRNA. Cell 159:148–62
    [Google Scholar]
97. Schwartz S, Mumbach MR, Jovanovic M, Wang T, Maciag K et al. 2014b. Perturbation of m6A writers reveals two distinct classes of mRNA methylation at internal and 5′ sites. Cell Rep 8:284–96
    [Google Scholar]
98. Shi H, Wang X, Lu Z, Zhao BS, Ma H et al. 2017. YTHDF3 facilitates translation and decay of N⁶-methyladenosine-modified RNA. Cell Res 27:315–28
    [Google Scholar]
99. Shoshan E, Mobley AK, Braeuer RR, Kamiya T, Huang L et al. 2015. Reduced adenosine-to-inosine miR-455-5p editing promotes melanoma growth and metastasis. Nat. Cell Biol. 17:311–21
    [Google Scholar]
100. Sieron P, Hader C, Hatina J, Engers R, Wlazlinski A et al. 2009. DKC1 overexpression associated with prostate cancer progression. Br. J. Cancer 101:1410–16
     [Google Scholar]
101. Sledz P, Jinek M. 2016. Structural insights into the molecular mechanism of the m⁶A writer complex. eLife 5:e18434
     [Google Scholar]
102. Song CX, Yin S, Ma L, Wheeler A, Chen Y et al. 2017. 5-Hydroxymethylcytosine signatures in cell-free DNA provide information about tumor types and stages. Cell Res 27:1231–42
     [Google Scholar]
103. Squires JE, Patel HR, Nousch M, Sibbritt T, Humphreys DT et al. 2012. Widespread occurrence of 5-methylcytosine in human coding and non-coding RNA. Nucleic Acids Res 40:5023–33
     [Google Scholar]
104. Su R, Dong L, Li C, Nachtergaele S, Wunderlich M et al. 2018. R-2HG exhibits anti-tumor activity by targeting FTO/m⁶A/MYC/CEBPA signaling. Cell 172:90–105.e23
     [Google Scholar]
105. Suzuki T, Ueda H, Okada S, Sakurai M 2015. Transcriptome-wide identification of adenosine-to-inosine editing using the ICE-seq method. Nat. Protoc. 10:715–32
     [Google Scholar]
106. Takahashi M, Yoshimoto T, Shimoda M, Kono T, Koizumi M et al. 2006. Loss of function of the candidate tumor suppressor prox1 by RNA mutation in human cancer cells. Neoplasia 8:1003–10
     [Google Scholar]
107. Tan A, Dang Y, Chen G, Mo Z 2015. Overexpression of the fat mass and obesity associated gene (FTO) in breast cancer and its clinical implications. Int. J. Clin. Exp. Pathol. 8:13405–10
     [Google Scholar]
108. Tan Y, Zheng J, Liu X, Lu M, Zhang C et al. 2018. Loss of nucleolar localization of NAT10 promotes cell migration and invasion in hepatocellular carcinoma. Biochem. Biophys. Res. Commun. 499:1032–38
     [Google Scholar]
109. Tasaki M, Shimada K, Kimura H, Tsujikawa K, Konishi N 2011. ALKBH3, a human AlkB homologue, contributes to cell survival in human non-small-cell lung cancer. Br. J. Cancer 104:700–6
     [Google Scholar]
110. Thomas D, Majeti R. 2017. Biology and relevance of human acute myeloid leukemia stem cells. Blood 129:1577–85
     [Google Scholar]
111. Tomaselli S, Galeano F, Alon S, Raho S, Galardi S et al. 2015. Modulation of microRNA editing, expression and processing by ADAR2 deaminase in glioblastoma. Genome Biol 16:5
     [Google Scholar]
112. Valleron W, Laprevotte E, Gautier EF, Quelen C, Demur C et al. 2012a. Specific small nucleolar RNA expression profiles in acute leukemia. Leukemia 26:2052–60
     [Google Scholar]
113. Valleron W, Ysebaert L, Berquet L, Fataccioli V, Quelen C et al. 2012b. Small nucleolar RNA expression profiling identifies potential prognostic markers in peripheral T-cell lymphoma. Blood 120:3997–4005
     [Google Scholar]
114. Visvanathan A, Patil V, Arora A, Hegde AS, Arivazhagan A et al. 2018. Essential role of METTL3-mediated m⁶A modification in glioma stem-like cells maintenance and radioresistance. Oncogene 37:522–33
     [Google Scholar]
115. Vu LP, Pickering BF, Cheng Y, Zaccara S, Nguyen D et al. 2017. The N⁶-methyladenosine (m⁶A)-forming enzyme METTL3 controls myeloid differentiation of normal hematopoietic and leukemia cells. Nat. Med. 23:1369–76
     [Google Scholar]
116. Wang P, Doxtader KA, Nam Y 2016. Structural basis for cooperative function of Mettl3 and Mettl14 methyltransferases. Mol. Cell 63:306–17
     [Google Scholar]
117. Wang X, Feng J, Xue Y, Guan Z, Zhang D et al. 2016. Structural basis of N⁶-adenosine methylation by the METTL3-METTL14 complex. Nature 534:575–78
     [Google Scholar]
118. Wang X, Lu Z, Gomez A, Hon GC, Yue Y et al. 2014. N6-methyladenosine-dependent regulation of messenger RNA stability. Nature 505:117–20
     [Google Scholar]
119. Wang X, Zhao BS, Roundtree IA, Lu Z, Han D et al. 2015. N⁶-methyladenosine modulates messenger RNA translation efficiency. Cell 161:1388–99
     [Google Scholar]
120. Wang Y, Xu X, Yu S, Jeong KJ, Zhou Z et al. 2017. Systematic characterization of A-to-I RNA editing hotspots in microRNAs across human cancers. Genome Res 27:1112–25
     [Google Scholar]
121. Weissman SM, Lewis M, Karon M 1963. Pseudouridine metabolism. IV. Excretion of pseudouridine and other nitrogenous metabolites in chronic leukemia. Blood 22:657–63
     [Google Scholar]
122. Wen J, Lv R, Ma H, Shen H, He C et al. 2018. Zc3h13 regulates nuclear RNA m⁶A methylation and mouse embryonic stem cell self-renewal. Mol. Cell 69:1028–38.e6
     [Google Scholar]
123. Weng H, Huang H, Wu H, Qin X, Zhao BS et al. 2018. METTL14 inhibits hematopoietic stem/progenitor differentiation and promotes leukemogenesis via mRNA m⁶A modification. Cell Stem Cell 22:191–205.e
     [Google Scholar]
124. Wojtas MN, Pandey RR, Mendel M, Homolka D, Sachidanandam R, Pillai RS 2017. Regulation of m⁶A transcripts by the 3′→5′ RNA helicase YTHDC2 is essential for a successful meiotic program in the mammalian germline. Mol. Cell 68:374–87.e12
     [Google Scholar]
125. Woo HH, Chambers SK. 2019. Human ALKBH3-induced m¹A demethylation increases the CSF-1 mRNA stability in breast and ovarian cancer cells. Biochim. Biophys. Acta Gene Regul. Mech. 1862:35–46
     [Google Scholar]
126. Wu B, Su S, Patil DP, Liu H, Gan J et al. 2018. Molecular basis for the specific and multivariant recognitions of RNA substrates by human hnRNP A2/B1. Nat. Commun. 9:420
     [Google Scholar]
127. Wu G, Xiao M, Yang C, Yu YT 2011. U2 snRNA is inducibly pseudouridylated at novel sites by Pus7p and snR81 RNP. EMBO J 30:79–89
     [Google Scholar]
128. Xiao W, Adhikari S, Dahal U, Chen YS, Hao YJ et al. 2016. Nuclear m⁶A reader YTHDC1 regulates mRNA splicing. Mol. Cell 61:507–19
     [Google Scholar]
129. Xu H, Jiang B, Meng L, Ren T, Zeng Y et al. 2012. N-α-acetyltransferase 10 protein inhibits apoptosis through RelA/p65-regulated MCL1 expression. Carcinogenesis 33:1193–202
     [Google Scholar]
130. Xuan JJ, Sun WJ, Lin PH, Zhou KR, Liu S et al. 2018. RMBase v2.0: deciphering the map of RNA modifications from epitranscriptome sequencing data. Nucleic Acids Res 46:D327–34
     [Google Scholar]
131. Yan F, Al-Kali A, Zhang Z, Liu J, Pang J et al. 2018. A dynamic N⁶-methyladenosine methylome regulates intrinsic and acquired resistance to tyrosine kinase inhibitors. Cell Res 28:1062–76
     [Google Scholar]
132. Yang F, Jin H, Que B, Chao Y, Zhang H et al. 2019. Dynamic m⁶A mRNA methylation reveals the role of METTL3-m⁶A-CDCP1 signaling axis in chemical carcinogenesis. Oncogene 38:4755–72
     [Google Scholar]
133. Yang JC, Risch E, Zhang M, Huang C, Huang H, Lu L 2017. Association of tRNA methyltransferase NSUN2/IGF-II molecular signature with ovarian cancer survival. Future Oncol 13:1981–90
     [Google Scholar]
134. Yang W, Chendrimada TP, Wang Q, Higuchi M, Seeburg PH et al. 2006. Modulation of microRNA processing and expression through RNA editing by ADAR deaminases. Nat. Struct. Mol. Biol. 13:13–21
     [Google Scholar]
135. Yang X, Yang Y, Sun BF, Chen YS, Xu JW et al. 2017. 5-methylcytosine promotes mRNA export—NSUN2 as the methyltransferase and ALYREF as an m⁵C reader. Cell Res 27:606–25
     [Google Scholar]
136. Yang Z, Li J, Feng G, Gao S, Wang Y et al. 2017. MicroRNA-145 modulates N⁶-methyladenosine levels by targeting the 3′-untranslated mRNA region of the N⁶-methyladenosine binding YTH domain family 2 protein. J. Biol. Chem. 292:3614–23
     [Google Scholar]
137. Yao QJ, Sang L, Lin M, Yin X, Dong W et al. 2018. Mettl3–Mettl14 methyltransferase complex regulates the quiescence of adult hematopoietic stem cells. Cell Res 28:952–54
     [Google Scholar]
138. Yi J, Gao R, Chen Y, Yang Z, Han P et al. 2017. Overexpression of NSUN2 by DNA hypomethylation is associated with metastatic progression in human breast cancer. Oncotarget 8:20751–65
     [Google Scholar]
139. Yoon A, Peng G, Brandenburger Y, Zollo O, Xu W et al. 2006. Impaired control of IRES-mediated translation in X-linked dyskeratosis congenita. Science 312:902–6
     [Google Scholar]
140. Yue Y, Liu J, Cui X, Cao J, Luo G et al. 2018. VIRMA mediates preferential m⁶A mRNA methylation in 3′UTR and near stop codon and associates with alternative polyadenylation. Cell Discov 4:10
     [Google Scholar]
141. Zhang C, Chen Y, Sun B, Wang L, Yang Y et al. 2017. m⁶A modulates haematopoietic stem and progenitor cell specification. Nature 549:273–76
     [Google Scholar]
142. Zhang C, Samanta D, Lu H, Bullen JW, Zhang H et al. 2016a. Hypoxia induces the breast cancer stem cell phenotype by HIF-dependent and ALKBH5-mediated m⁶A-demethylation of NANOG mRNA. PNAS 113:E2047–56
     [Google Scholar]
143. Zhang C, Zhi WI, Lu H, Samanta D, Chen I et al. 2016b. Hypoxia-inducible factors regulate pluripotency factor expression by ZNF217- and ALKBH5-mediated modulation of RNA methylation in breast cancer cells. Oncotarget 7:64527–42
     [Google Scholar]
144. Zhang H, Hou W, Wang HL, Liu HJ, Jia XY et al. 2014. GSK-3β–regulated N-acetyltransferase 10 is involved in colorectal cancer invasion. Clin. Cancer Res. 20:4717–29
     [Google Scholar]
145. Zhang L, Yang CS, Varelas X, Monti S 2016. Altered RNA editing in 3′ UTR perturbs microRNA-mediated regulation of oncogenes and tumor-suppressors. Sci. Rep. 6:23226
     [Google Scholar]
146. Zhang S, Zhao BS, Zhou A, Lin K, Zheng S et al. 2017. m⁶A demethylase ALKBH5 maintains tumorigenicity of glioblastoma stem-like cells by sustaining FOXM1 expression and cell proliferation program. Cancer Cell 31:591–606.e6
     [Google Scholar]
147. Zhang X, Liu J, Yan S, Huang K, Bai Y, Zheng S 2015. High expression of N-acetyltransferase 10: a novel independent prognostic marker of worse outcome in patients with hepatocellular carcinoma. Int. J. Clin. Exp. Pathol. 8:14765–71
     [Google Scholar]
148. Zhao X, Chen Y, Mao Q, Jiang X, Jiang W et al. 2018. Overexpression of YTHDF1 is associated with poor prognosis in patients with hepatocellular carcinoma. Cancer Biomark 21:859–68
     [Google Scholar]
149. Zheng G, Dahl JA, Niu Y, Fedorcsak P, Huang CM et al. 2013. ALKBH5 is a mammalian RNA demethylase that impacts RNA metabolism and mouse fertility. Mol. Cell 49:18–29
     [Google Scholar]
150. Zhong L, Liao D, Zhang M, Zeng C, Li X et al. 2019. YTHDF2 suppresses cell proliferation and growth via destabilizing the EGFR mRNA in hepatocellular carcinoma. Cancer Lett 442:252–61
     [Google Scholar]
151. Zhou S, Bai ZL, Xia D, Zhao ZJ, Zhao R et al. 2018. FTO regulates the chemo-radiotherapy resistance of cervical squamous cell carcinoma (CSCC) by targeting β-catenin through mRNA demethylation. Mol. Carcinog. 57:590–97
     [Google Scholar]
152. Zipeto MA, Court AC, Sadarangani A, Delos Santos NP, Balaian L et al. 2016. ADAR1 activation drives leukemia stem cell self-renewal by impairing let-7 biogenesis. Cell Stem Cell 19:177–91
     [Google Scholar]